Microbot Medical Inc. announced the FDA clearance of the LIBERTY® Endovascular Robotic System, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The CEO will discuss this at the H.C. Wainwright Annual Investor Conference on September 9th at 9:00am ET. Microbot Medical is a medical device company focused on transforming endovascular procedures with advanced robotic technology. The company’s goal is to drive the future of endovascular care. Forward-looking statements regarding future financial results and growth opportunities were also made. More information can be found on the company’s website and SEC reports.

Read more at GlobeNewswire: Microbot Medical to Highlight FDA 510(k)